Discovery of BIO-8169─A Highly Potent, Selective, and Brain-Penetrant IRAK4 Inhibitor for the Treatment of Neuroinflammation-Reference-Cited by-同舟云学术

Discovery of BIO-8169─A Highly Potent, Selective, and Brain-Penetrant IRAK4 Inhibitor for the Treatment of Neuroinflammation

Published:2024-05-02 Issue:10 Volume:67 Page:8383-8395
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Pfaffenbach Magnus¹^ORCID,Bolduc Philippe N.¹^ORCID,Xin Zhili¹,Gao Fang¹,Evans Ryan¹,Fang Terry²,Chodaparambil Jayanth V.³,Henry Kate L.²,Li Pei⁴^ORCID,Mathieu Steven⁵,Metrick Claire³,Vera Rebollar Jorge A.⁶,Gu Rong-Fang⁷,Mccarl Christie-Ann⁶,Silbereis John⁶,Peterson Emily A.¹^ORCID

Affiliation:

1. Department of Medicinal Chemistry, Biogen Inc., 225 Binney Street, Cambridge, Massachusetts 02142, United States

2. Department of Acute Neurology, Biogen Inc., 225 Binney Street, Cambridge, Massachusetts 02142, United States

3. Physical Biochemistry, Biogen Inc., 225 Binney Street, Cambridge, Massachusetts 02142, United States

4. Drug Metabolism and Pharmacokinetics, Biogen Inc., 225 Binney Street, Cambridge, Massachusetts 02142, United States

5. Pharmaceutical Operations & Technology, Biogen Inc., 225 Binney Street, Cambridge, Massachusetts 02142, United States

6. Department of Multiple Sclerosis and Immunology, Biogen Inc., 225 Binney Street, Cambridge, Massachusetts 02142, United States

7. Chemical Biology and Proteomics, Biogen Inc., Cambridge, Massachusetts 02142, United States

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.4c00560

Reference32 articles.

1. Multiple Sclerosis

2. A lymphocyte–microglia–astrocyte axis in chronic active multiple sclerosis

3. Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis

4. Multiple sclerosis progression: time for a new mechanism-driven framework

5. Recent Advances in the Discovery of Small Molecule Inhibitors of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) as a Therapeutic Target for Inflammation and Oncology Disorders